TWI268777B - Compounds with 5-HT1A activity useful for treating disorders of the outer retina - Google Patents

Compounds with 5-HT1A activity useful for treating disorders of the outer retina Download PDF

Info

Publication number
TWI268777B
TWI268777B TW090106235A TW90106235A TWI268777B TW I268777 B TWI268777 B TW I268777B TW 090106235 A TW090106235 A TW 090106235A TW 90106235 A TW90106235 A TW 90106235A TW I268777 B TWI268777 B TW I268777B
Authority
TW
Taiwan
Prior art keywords
retinal
pharmaceutical composition
rats
retina
org
Prior art date
Application number
TW090106235A
Other languages
English (en)
Chinese (zh)
Inventor
Robert J Collier Jr
Michael A Kapin
Mark R Hellberg
Thomas R Dean
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Application granted granted Critical
Publication of TWI268777B publication Critical patent/TWI268777B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Liquid Crystal Substances (AREA)
  • Indole Compounds (AREA)
TW090106235A 2000-03-17 2001-03-16 Compounds with 5-HT1A activity useful for treating disorders of the outer retina TWI268777B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19027900P 2000-03-17 2000-03-17

Publications (1)

Publication Number Publication Date
TWI268777B true TWI268777B (en) 2006-12-21

Family

ID=22700682

Family Applications (1)

Application Number Title Priority Date Filing Date
TW090106235A TWI268777B (en) 2000-03-17 2001-03-16 Compounds with 5-HT1A activity useful for treating disorders of the outer retina

Country Status (18)

Country Link
EP (3) EP1263434A1 (enExample)
JP (5) JP2003527423A (enExample)
KR (3) KR20030016239A (enExample)
CN (2) CN1418100A (enExample)
AR (1) AR028258A1 (enExample)
AT (1) ATE247507T1 (enExample)
AU (5) AU2001238552A1 (enExample)
BR (3) BR0109193A (enExample)
CA (3) CA2400637A1 (enExample)
DE (1) DE60100625T2 (enExample)
DK (1) DK1263504T3 (enExample)
ES (1) ES2204848T3 (enExample)
MX (3) MXPA02009071A (enExample)
PL (1) PL203709B1 (enExample)
PT (1) PT1263504E (enExample)
TW (1) TWI268777B (enExample)
WO (3) WO2001070223A1 (enExample)
ZA (1) ZA200206350B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6960579B1 (en) 1998-05-19 2005-11-01 Alcon Manufacturing, Ltd. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
EP1263434A1 (en) * 2000-03-17 2002-12-11 Alcon, Inc Compounds with 5-ht 2 and 5-ht 1a agonist activity for treating glaucoma
US20030207890A1 (en) 2001-02-23 2003-11-06 Collier Robert J Compounds with 5-ht1a activity useful for treating disorders of the outer retina
TW593302B (en) 2001-12-20 2004-06-21 Alcon Inc Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma
AU2003300915B2 (en) 2002-12-13 2008-08-28 Alcon, Inc. Novel benzopyran analogs and their use for the treatment of glaucoma
JP2004262812A (ja) * 2003-02-28 2004-09-24 Rohto Pharmaceut Co Ltd 眼圧低下剤
CA2520813C (en) * 2003-04-25 2009-10-27 Mitsubishi Pharma Corporation Sustained release formulations of alkylene dioxybenzene derivatives useful as 5-ht1a agonists
WO2005053688A1 (en) 2003-11-26 2005-06-16 Alcon, Inc. Substituted furo[2,3-g] indazoles for the treatment of glaucoma
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
US7129257B1 (en) 2003-12-15 2006-10-31 Alcon, Inc. Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
AR046890A1 (es) 2003-12-15 2005-12-28 Alcon Inc [1,4] oxazino [2,3-g] indazoles sustituidos para el tratamiento del glaucoma.
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
EP2400300A1 (en) 2004-08-25 2011-12-28 Takeda Pharmaceutical Company Limited Method of screening preventives/remedies for stress urinary incontinence
WO2006062839A1 (en) 2004-12-08 2006-06-15 Alcon, Inc. Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma
WO2007132841A1 (ja) 2006-05-16 2007-11-22 Takeda Pharmaceutical Company Limited 縮合複素環化合物およびその用途
WO2008024846A2 (en) * 2006-08-25 2008-02-28 Allergan, Inc. Brimonidine and timolol compositions
EP2896624B1 (en) 2007-03-28 2016-07-13 Atir Holding S.A. Heterotricyclic compounds as serotonergic and/or dopaminergic agents and uses thereof
JP5520051B2 (ja) 2007-11-15 2014-06-11 武田薬品工業株式会社 縮合ピリジン誘導体およびその用途
TW201010727A (en) * 2008-09-03 2010-03-16 Alcon Res Ltd Pharmaceutical composition having relatively low ionic strength
US20110124736A1 (en) 2009-11-09 2011-05-26 Allergan, Inc. Compositions and methods for stimulating hair growth
JPWO2011071136A1 (ja) 2009-12-11 2013-04-22 アステラス製薬株式会社 線維筋痛症治療剤
RU2641021C2 (ru) 2013-02-15 2018-01-17 Аллерган, Инк. Имплантат для пролонгированной доставки лекарственного средства
WO2018064465A1 (en) 2016-09-29 2018-04-05 The Regents Of The University Of California Compounds for increasing neural plasticity
US20210052600A1 (en) 2017-12-27 2021-02-25 Takeda Pharmaceutical Company Limited Therapeutic agents for stress urinary incontinence and incotinence of feces
CA3130770A1 (en) 2019-02-27 2020-09-03 The Regents Of The University Of California Azepino-indoles and other heterocycles for treating brain disorders
KR20210134928A (ko) 2019-02-27 2021-11-11 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 뇌 장애를 치료하기 위한 n-치환된 인돌 및 다른 헤테로사이클
TW202333668A (zh) 2021-12-15 2023-09-01 美商德利克斯醫療公司 經苯氧基及苄氧基取代之精神成形素(psychoplastogen)及其用途
JP2024546180A (ja) * 2021-12-23 2024-12-17 シルケア ディーイーヴィ 聴覚疾患の治療のための４－フェニル－テトラヒドロピリジン誘導体

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02262518A (ja) * 1989-04-03 1990-10-25 Kaken Pharmaceut Co Ltd 眼圧調整剤
JP2824863B2 (ja) * 1989-07-12 1998-11-18 エーザイ株式会社 α▲下１▼―ブロッカー点眼剤
TW270114B (enExample) * 1993-10-22 1996-02-11 Hoffmann La Roche
US5521183A (en) * 1994-08-30 1996-05-28 Allergan Use of 5-HT ligands as anti-pruritic agents
US5998467A (en) * 1995-10-25 1999-12-07 Mitsubishi Chemical Corporation Medicine for oculopathy
JP3958391B2 (ja) * 1995-10-25 2007-08-15 三菱化学株式会社 眼疾患用薬剤
WO1998018458A1 (en) * 1996-10-31 1998-05-07 Alcon Laboratories, Inc. Opthalmological compositions containing serotonin 5-ht1a receptor agonist and their use in the treatment of glaucoma
DE19751949A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
GB9819033D0 (en) * 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds VI
EP1263434A1 (en) * 2000-03-17 2002-12-11 Alcon, Inc Compounds with 5-ht 2 and 5-ht 1a agonist activity for treating glaucoma

Also Published As

Publication number Publication date
KR20020082885A (ko) 2002-10-31
AU2001238552A1 (en) 2001-10-03
BR0109211A (pt) 2003-02-11
MXPA02009071A (es) 2003-05-23
PL203709B1 (pl) 2009-11-30
HK1051504A1 (en) 2003-08-08
AU2005202600B2 (en) 2008-07-31
AR028258A1 (es) 2003-04-30
KR100749191B1 (ko) 2007-08-13
MXPA02009072A (es) 2003-03-12
DE60100625D1 (de) 2003-09-25
CN1198605C (zh) 2005-04-27
CN1418121A (zh) 2003-05-14
DK1263504T3 (da) 2003-12-08
EP1263504A2 (en) 2002-12-11
BR0109230A (pt) 2003-06-03
PT1263504E (pt) 2003-12-31
KR20030016239A (ko) 2003-02-26
CA2400639C (en) 2011-08-16
JP2003527423A (ja) 2003-09-16
CN1418100A (zh) 2003-05-14
ZA200206350B (en) 2003-08-08
CA2400639A1 (en) 2001-09-27
CA2399985A1 (en) 2001-09-27
WO2001070222A2 (en) 2001-09-27
DE60100625T2 (de) 2004-02-26
EP1263504B1 (en) 2003-08-20
WO2001070222A3 (en) 2002-07-25
JP4789231B2 (ja) 2011-10-12
JP2011037901A (ja) 2011-02-24
ES2204848T3 (es) 2004-05-01
JP2003527422A (ja) 2003-09-16
WO2001070230A2 (en) 2001-09-27
BR0109193A (pt) 2003-05-27
WO2001070223A1 (en) 2001-09-27
JP2011153158A (ja) 2011-08-11
PL358306A1 (en) 2004-08-09
JP2003527427A (ja) 2003-09-16
CA2400637A1 (en) 2001-09-27
AU2001245310B2 (en) 2005-03-17
AU2005202600A1 (en) 2005-07-07
AU4531001A (en) 2001-10-03
KR20030009390A (ko) 2003-01-29
MXPA02009073A (es) 2003-03-12
AU2001239836A1 (en) 2001-10-03
ATE247507T1 (de) 2003-09-15
EP1263434A1 (en) 2002-12-11
EP1267878A2 (en) 2003-01-02
WO2001070230A3 (en) 2002-04-25

Similar Documents

Publication Publication Date Title
TWI268777B (en) Compounds with 5-HT1A activity useful for treating disorders of the outer retina
AU2001245310A1 (en) Compounds with 5-HT1A activity useful for treating disorders of the outer retina
US20100168121A1 (en) Compounds with 5-ht1a activity useful for treating disorders of the outer retina
DE69423782T2 (de) Verwendung von nichtsteroidalen cyclooxygenasehemmern zur herstellung eines medikaments zur behandlung vom erhoehten augeninnendruck
Collier et al. Agonists at the serotonin receptor (5-HT1A) protect the retina from severe photo-oxidative stress
WO2004069181A2 (en) Composition for the treatment of intraocular pressure
KR20020002356A (ko) 외부 망막 손상의 치료
PL214875B1 (pl) Zastosowanie antagonistów receptorów ß-adrenergicznych do wytwarzania leku do leczenia zaburzen zewnetrznej siatkówki
WO2005079792A1 (ja) 重症糖尿病網膜症の予防又は治療剤
ERICKSON et al. Adrenergic regulation of aqueous outflow
HK1051504B (en) Use of compounds with 5-ht1a activity useful for treating disorders of the outer retina
US20110160308A1 (en) Use of Monoamine Oxidase Inhibitors to Treat Outer Retina Disorders

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees